Cargando…
INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES
BTFC travel award recipient Patients with brain metastases (BM) face a 90% mortality rate within one year of diagnosis because the current standard of care is mainly palliative. Our patient-derived xenograft models have successfully recapitulated all the stages of the metastatic cascade and captured...
Autores principales: | Kieliszek, A M, Mobilio, D, Bassey-Archibong, B I, Johnson, J W, Piotrowski, M L, Aghaei, N, Gwynne, W D, Escudero, L, Chafe, S, Zhang, K Zhai1 C, Quaile, A, McKenna, D, Subapanditha, M, de Araujo, E D, Sedighi, A, Gunning, P T, Tokar, T, Venugopal, C, Montenegro-Burke, J R, Magolan, J, Singh, S K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337573/ http://dx.doi.org/10.1093/noajnl/vdad071.007 |
Ejemplares similares
-
An HLA-G/SPAG9/STAT3 axis promotes brain metastases
por: Bassey-Archibong, Blessing Iquo, et al.
Publicado: (2023) -
47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES
por: Bassey-Archibong, Blessing, et al.
Publicado: (2020) -
BSCI-22 DETERMINING THE EFFECT OF NOVEL SMALL MOLECULE DRUGS AGAINST THE MIGRATION OF BRAIN METASTASIS INITIATING CELLS (BMICS)
por: Mobilio, Daniel, et al.
Publicado: (2022) -
39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS
por: Kieliszek, Agata, et al.
Publicado: (2020) -
BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES
por: Singh, Sheila, et al.
Publicado: (2019)